Drug Profile
Research programme: filariasis therapeutics - Eisai/Liverpool School of Tropical Medicine/University of Liverpool
Latest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Eisai Co Ltd; Liverpool School of Tropical Medicine; University of Liverpool
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Filariasis
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for research development in Filariasis in United Kingdom
- 30 Mar 2020 Early research development is ongoing (Esai's piepline, April 2020)
- 28 Jul 2018 No recent reports of development identified for research development in Filariasis in United Kingdom